The Next Stock You Should Consider: GlaxoSmithKline plc (ADR) (GSK)

Some of the best-performing stocks over the past several decades boast long histories of paying dividends to shareholders.  Moreover, if these stocks sell for an apparent discount to their intrinsic values, they might deserve a place in your portfolio. In my opinion, GlaxoSmithKline plc (ADR) (NYSE:GSK) offers both great dividend growth and impressive value. Here’s why you may want to give this notable drugmaker a closer look.

Company Performance in Review

Glaxo is a UK-based, $109 billion pharmaceutical company with a broad array of products.  The company operates through three segments:  Pharmaceuticals, Vaccines, and Consumer Healthcare.  Pharmaceutical products make up the bulk of Glaxo’s business, comprising 68% of the company’s sales.  The Vaccines and Consumer Healthcare groups account for 13% and 19% of sales, respectively.  Glaxo’s business is spread across the world.  The United States provides the most business for the company, but Glaxo derives 68% of its sales from outside the U.S.

GlaxoSmithKline plc (ADR) (NYSE:GSK)Glaxo’s 2012 results were challenged by the continued economic struggles in Europe.  The company reported revenues declined 1% on a constant currency basis in 2012 as compared to the prior year, and full-year earnings per share of $2.91.  While these results aren’t exactly reasons to jump for joy, Glaxo’s sales held up much better than its peers Eli Lilly & Co. (NYSE:LLY) and Pfizer Inc. NYSE:PFE).

Going forward, Glaxo’s growth will be fueled by continued emerging market expansion.  The company plans to continue building its emerging market segment to capitalize on growth in the developing international economies.  This will be accomplished through a combination of organic investment as well as targeted bolt-on acquisitions.

Pfizer’s Pipeline Uncertainties

Pfizer announced solid full-year 2012 results.  The company’s reported diluted earnings per share came in at $1.94.  While the company is currently trading for a reasonable 14 times these earnings, full-year 2012 revenues declined 10%. Management blamed the loss of Lipitor for the bulk of the decline.

You might be concerned about Pfizer losing Lipitor, and for good reason.  Lipitor accounted for $9.6 billion in sales for Pfizer in 2011, almost as much as the company’s next three best-selling products combined. The company will have to allocate significant resources if it wants to replace these lost sales, which will take a toll on the company’s bottom line going forward.  Indeed, Pfizer is forecasting reported diluted earnings per share to be in a range of $1.50 to $1.65 for fiscal year 2013.  As a result, the company is trading for more than 17 times the midpoint of its guided 2013 range.

Glaxo doesn’t have the same level of risk associated with its product pipeline.  Although Glaxo’s Pharmaceuticals and Vaccines segment accounts for more than 60% of its sales, no one therapeutic area within that segment accounts for more than a third of its sales.  Plainly stated, the company isn’t as reliant on one blockbuster drug as Pfizer was with Lipitor.

Eli Lilly’s Stalled Dividend

Meanwhile, Eli Lilly reported full-year 2012 revenues declined 7% year over year and earnings of $3.66 per share.  Consequently, the stock now trades for a modest 15 times trailing earnings.  While Eli Lilly’s share price has performed very well recently, increasing more than 20% in 2012, the company hasn’t provided investors with a dividend increase in almost three years.  Because its stock price has risen so much over the last couple years, the yield is now down to 3.5% at recent prices.  Going forward, management hasn’t provided guidance as to when the company will resume increasing its payout.

As opposed to Lilly’s inability to raise its dividend, Glaxo’s management remains steadfast in their commitment to increasing its payout. The company declared a fourth-quarter dividend higher than its quarterly payout last year.  Glaxo’s four quarterly dividends in 2012 amounted to 74 pence versus 70 pence in 2011, an increase of more than 5% year over year.  Since Glaxo’s stock price leveled off (the stock actually ended 2012 down slightly), new investors will enjoy a yield of more than 5% annualized.

The Foolish Bottom Line

Glaxo doesn’t have the pipeline problems that Pfizer has and also has a more shareholder-friendly dividend policy than Eli Lilly.  While both Eli Lilly and Pfizer had great runs last year, their dividend yields now pale in comparison to Glaxo’s 5% yield.

Pharmaceutical companies like Glaxo provide products that customers can’t go without for very long.  In addition, the company offers an industry (and market) beating dividend yield.  To top it all off, the stock is trading for valuation multiples more attractive than the S&P 500.  The company has all the makings of a highly rewarding long-term holding.  Glaxo and its juicy dividend yield belong in many investors’ portfolios.

The article The Next Stock You Should Consider originally appeared on Fool.com and is written by Robert Ciura.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

The 10 Most Expensive Cruise Ships in the World

The 10 Fastest Supercomputers in the World

The 10 Best Countries for Doing Business 2015

6 Most Expensive Fruits In The World

10 Worst Airlines in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!